Opportunity Information: Apply for PAR 21 346
This NIH funding opportunity (PAR-21-346) is a limited competition cooperative agreement (U24; clinical trials not allowed) to continue support for the Coordinating Center for the Small Cell Lung Cancer (SCLC) Consortium. The overall goal is to keep the Consortium functioning as a coordinated, shared-resource network focused on SCLC prevention, diagnosis, treatment, and understanding how treatment resistance develops. Rather than funding a stand-alone research project, the award is meant to fund the infrastructure and centralized services that allow multiple Consortium research groups to work from common data standards, shared biospecimens, shared model systems, and consistent analytic approaches.
The Coordinating Center is expected to run the day-to-day and strategic administrative operations of the Consortium. That includes organizing governance and consortium activities, coordinating communications across member sites, and supporting meetings and other routine collaborative processes. In practice, this is the hub that keeps participating projects aligned, ensures policies are followed consistently, and helps the Consortium operate as a single program rather than a set of disconnected labs.
A major technical responsibility is the creation and ongoing support of databases for omics and other Consortium-relevant data. The Coordinating Center is expected to set up and maintain data systems that can accept, curate, harmonize, and distribute data generated across member groups. This implies developing common data elements, metadata standards, quality control checks, secure access and sharing workflows, and the ability to integrate diverse data types. The emphasis on omics suggests the data environment should be able to handle large-scale molecular datasets alongside clinical, pathological, and experimental annotations as applicable to the Consortium.
The opportunity also calls for centralized tissue banking and a virtual biospecimen database. The Coordinating Center should secure centralized banking for specimens submitted by Consortium members and maintain a virtual inventory that covers all tissue resources across the Consortium. This means the CC is responsible for tracking what biospecimens exist, where they are stored, what consent and use limitations apply, how they are annotated, and how members request and receive materials. The virtual biospecimen database is meant to make the Consortiums tissue assets discoverable and usable without forcing every study team to rebuild its own tracking system.
In addition, the Coordinating Center must provide centralized biostatistics, bioinformatics, and data analysis support. This role generally includes helping investigators design analyses, apply consistent statistical methods, develop pipelines for multi-omics integration, and perform cross-project analyses that become possible only when data are pooled. Centralizing these capabilities is intended to improve reproducibility, reduce duplication of effort, and make it easier to compare results across sites and studies.
The FOA also emphasizes creating and maintaining SCLC model repositories and distribution units for in vivo and in vitro models. The Coordinating Center is expected to establish shared repositories of Consortium-developed or Consortium-curated models (for example, cell lines, organoids, xenografts, genetically engineered mouse models, or related tools, depending on what the Consortium uses) and to manage distribution so other members can access them efficiently. This supports standardization and accelerates follow-up studies by ensuring that model systems can be replicated and shared across research groups.
On the coordination and outreach side, the Coordinating Center is expected to support meeting planning and communications among Consortium members and to create and maintain a Consortium website. The website typically serves as a central point for Consortium information, resources, policies, and potentially controlled-access portals for data and resource requests, depending on the structure approved by NIH and Consortium leadership.
From an administrative standpoint, the funding instrument is a cooperative agreement, meaning NIH is expected to have substantial programmatic involvement compared with a standard grant. The activity category is listed under Education and Health, and the CFDA numbers are 93.393 and 93.394. The opportunity lists an award ceiling of $940,000. The original closing date shown is 2021-11-17, and the FOA was created on 2021-09-29.
Eligibility is restricted because this is a limited competition. The listing includes small businesses as eligible applicants, but the FOA language also notes important limitations on non-U.S. participation: non-domestic (non-U.S.) entities are not eligible to apply, and non-domestic components of U.S. organizations are not eligible to apply. At the same time, foreign components, as defined in the NIH Grants Policy Statement, are allowed, meaning a U.S. applicant organization may include certain foreign collaborations or elements if they meet NIH policy requirements. The FOA directs applicants to review the full announcement for the detailed eligibility rules and definitions that govern those distinctions.Apply for PAR 21 346
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Limited Competition: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.394.
- This funding opportunity was created on 2021-09-29.
- Applicants must submit their applications by 2021-11-17. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $940,000.00 in funding.
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is PAR-21-346?
PAR-21-346 is an NIH funding opportunity for a limited competition cooperative agreement (U24) to continue support for the Coordinating Center for the Small Cell Lung Cancer (SCLC) Consortium.
What is the purpose of this funding opportunity?
The purpose is to support the infrastructure and centralized services that keep the SCLC Consortium operating as a coordinated, shared-resource network focused on SCLC prevention, diagnosis, treatment, and understanding how treatment resistance develops. It is not intended to fund a stand-alone research project.
What does it mean that this is a "limited competition" opportunity?
It means eligibility is restricted. Applicants must follow the FOA's limited competition requirements and review the full announcement for the specific eligibility rules.
What NIH activity code and mechanism are used?
The award uses a U24 cooperative agreement mechanism.
Are clinical trials allowed under this opportunity?
No. Clinical trials are not allowed under this funding opportunity.
What does a cooperative agreement imply for NIH involvement?
Because this is a cooperative agreement, NIH is expected to have substantial programmatic involvement compared with a standard grant.
What is being funded if not a stand-alone research project?
The award is meant to fund the Coordinating Center's core infrastructure and centralized services that enable multiple Consortium research groups to operate using common data standards, shared biospecimens, shared model systems, and consistent analytic approaches.
What are the Coordinating Center's main administrative responsibilities?
The Coordinating Center is expected to run day-to-day and strategic administrative operations for the Consortium, including organizing governance and consortium activities, coordinating communications across member sites, and supporting meetings and routine collaborative processes to keep projects aligned and policies applied consistently.
What data responsibilities does the Coordinating Center have?
A major responsibility is creating and maintaining databases for omics and other Consortium-relevant data. The Coordinating Center is expected to build and operate systems that can accept, curate, harmonize, and distribute data generated across member groups.
What kinds of data capabilities are expected for the databases?
Based on the description, the data environment is expected to support common data elements and metadata standards, quality control checks, secure access and sharing workflows, and integration of diverse data types. The emphasis on omics indicates an ability to handle large-scale molecular datasets alongside relevant clinical, pathological, and experimental annotations as applicable across the Consortium.
What is meant by centralized tissue banking in this opportunity?
The Coordinating Center is expected to secure centralized banking for specimens submitted by Consortium members and to support Consortium-wide access to tissue resources through centralized processes.
What is a virtual biospecimen database and what is it used for?
The virtual biospecimen database is an inventory covering tissue resources across the Consortium. It is meant to track what biospecimens exist, where they are stored, what consent and use limitations apply, how they are annotated, and how members request and receive materials, making tissue assets discoverable and usable across the network.
What analysis support is the Coordinating Center expected to provide?
The Coordinating Center must provide centralized biostatistics, bioinformatics, and data analysis support. This includes supporting consistent statistical methods, developing analysis pipelines (including for multi-omics integration), and enabling cross-project analyses that rely on pooled data.
Why does the FOA emphasize centralized analysis capabilities?
Centralizing biostatistics and bioinformatics is intended to improve reproducibility, reduce duplication of effort, and make it easier to compare results across sites and studies by using consistent analytic approaches.
What are SCLC model repositories and distribution units in this context?
The FOA calls for creating and maintaining repositories and distribution units for in vivo and in vitro SCLC models developed or curated by the Consortium. The Coordinating Center is expected to manage these shared model resources and handle distribution so member groups can access them efficiently.
What types of models might be included in the SCLC model repositories?
The opportunity lists examples such as cell lines, organoids, xenografts, genetically engineered mouse models, or related tools, depending on what the Consortium uses.
What communications and outreach functions are expected?
The Coordinating Center is expected to support meeting planning and communications among Consortium members and to create and maintain a Consortium website that serves as a central point for Consortium information, resources, and policies.
What might the Consortium website be used for?
Based on the description, the website typically serves as a central location for Consortium information, shared resources, and policies. It may also include controlled-access portals for data and resource requests, depending on what is approved by NIH and Consortium leadership.
What is the award ceiling for this opportunity?
The listed award ceiling is $940,000.
What are the CFDA numbers associated with this opportunity?
The CFDA numbers listed are 93.393 and 93.394.
What general category is this opportunity listed under?
The activity category is listed under Education and Health.
What are the key dates provided for the FOA?
The FOA was created on 2021-09-29, and the original closing date shown is 2021-11-17.
Who is eligible to apply?
Eligibility is restricted because this is a limited competition. The listing includes small businesses as eligible applicants, but applicants should rely on the full FOA for the detailed eligibility requirements.
Are non-U.S. (non-domestic) entities eligible to apply?
No. Non-domestic (non-U.S.) entities are not eligible to apply under this opportunity.
Are non-domestic components of U.S. organizations eligible to apply?
No. Non-domestic components of U.S. organizations are not eligible to apply.
Are foreign components allowed at all?
Yes. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. This means a U.S. applicant organization may include certain foreign collaborations or elements if they meet NIH policy requirements.
Where should applicants look for the definitive eligibility rules and definitions?
The FOA directs applicants to review the full announcement for detailed eligibility rules and for definitions governing concepts such as limited competition restrictions, non-domestic entities, non-domestic components, and foreign components.
Browse more opportunities from the same category: Education, Health
Next opportunity: HEAL Initiative: Advancing Health Equity in Pain Management (R61/R33 Clinical Trial Required)
Previous opportunity: Mexican Spotted Owl (MSO) Protected Activity Center (PAC) Thinning Project Sikes Act Cooperative Agreement via the Readiness and Environmental Protection Integration (REPI) Program in support of Naval Observatory Flagstaff Station (NOFS), Flagstaff, AZ
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 21 346
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 21 346) also looked into and applied for these:
| Funding Opportunity |
|---|
| Exploratory Grants in Cancer Control (R21 Clinical Trial Optional) Apply for PAR 21 341 Funding Number: PAR 21 341 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NIH Health Care Systems Research Collaboratory - Pragmatic and Implementation Trials of Embedded Interventions (UG3/UH3, Clinical Trials Optional) Apply for RFA AT 22 001 Funding Number: RFA AT 22 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Clinical Research Education and Career Development (CRECD) Program (R25-Independent Clinical Trial Not Allowed) Apply for PAR 21 347 Funding Number: PAR 21 347 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed) Apply for PAR 22 049 Funding Number: PAR 22 049 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials (CUSP2CT; U01 Clinical Trial Optional) Apply for RFA CA 21 063 Funding Number: RFA CA 21 063 Agency: National Institutes of Health Category: Education, Health Funding Amount: $450,000 |
| Clinical Sites for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required) Apply for RFA CA 21 047 Funding Number: RFA CA 21 047 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Coordinating Center for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (U24 Clinical Trial Required) Apply for RFA CA 21 045 Funding Number: RFA CA 21 045 Agency: National Institutes of Health Category: Education, Health Funding Amount: $750,000 |
| Research Bases for HIV/Cervical Cancer Prevention 'CASCADE' Clinical Trials Network (UG1 Clinical Trial Required) Apply for RFA CA 21 046 Funding Number: RFA CA 21 046 Agency: National Institutes of Health Category: Education, Health Funding Amount: $400,000 |
| Limited Competition: NIH Health Care Systems Research Collaboratory - Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA AT 22 002 Funding Number: RFA AT 22 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement (UG3/UH3, Clinical Trial Required) Apply for RFA AT 22 005 Funding Number: RFA AT 22 005 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain (UG3/UH3, Clinical Trials Optional) Apply for RFA AT 22 004 Funding Number: RFA AT 22 004 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed) Apply for PAR 22 062 Funding Number: PAR 22 062 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed) Apply for PAR 22 061 Funding Number: PAR 22 061 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) Apply for RFA CA 22 003 Funding Number: RFA CA 22 003 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) Apply for RFA CA 22 004 Funding Number: RFA CA 22 004 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required) Apply for RFA CA 21 062 Funding Number: RFA CA 21 062 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required) Apply for RFA CA 21 061 Funding Number: RFA CA 21 061 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed) Apply for RFA CA 21 060 Funding Number: RFA CA 21 060 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NIH HEAL Initiative: Preventing Opioid Misuse and Co-Occurring Conditions by Intervening on Social Determinants (R01 Clinical Trials Optional) Apply for RFA DA 22 036 Funding Number: RFA DA 22 036 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed) Apply for PAR 22 032 Funding Number: PAR 22 032 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 21 346", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.